Nizatidine

Catalog No.S1890 Batch:S189002

Print

Technical Data

Formula

C12H21N5O2S2
Molecular Weight 331.46 CAS No. 76963-41-2
Solubility (25°C)* In vitro DMSO 66 mg/mL (199.11 mM)
Water 22 mg/mL (66.37 mM)
Ethanol 5 mg/mL (15.08 mM)
In Vivo (Add solvents to the product individually and in order.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Nizatidine is a Histamine H2 receptor antagonist with an IC50 of 0.9 nM, and also inhibits AChE with an IC50 of 6.7 μM.
Targets
Histamine H2 receptor AChE
0.9 nM 6.7 μM
In vitro Nizatidine, a selective Histamine Receptor H2-receptor antagonist, is a potent inhibitor of gastric acid secretion, with an IC50 of 0.9 nM. This compound also reversibly inhibits acetylcholinesterase (AChE), with an IC50 of 6.7 μM, and the inhibition is noncompetitive, with a Ki value of 7.4 μM.
In Vivo Nizatidine exhibits maximal inhibition of gastric acid in rats within the first hour of drug administration, with EC50 of 1.383 μmol/kg. This compound (0.3-3 mg/kg, i.v.) significantly increases the motor index of gastrointestinal (GI) motility in a dose-dependent manner. It inhibits gastric acid secretion with ED50 and ED90 of 0.18 and 3.22 mg/kg in dogs, and 2.94 and 19.6 mg/kg in rats, respectively.

Protocol (from reference)

Animal Study:[1]
  • Animal Models

    Rat

  • Dosages

    0.5-10 μmol/kg

  • Administration

    s.c

References

  • https://pubmed.ncbi.nlm.nih.gov/2877081/
  • https://pubmed.ncbi.nlm.nih.gov/8093722/

Sellecks Nizatidine Has Been Cited by 4 Publications

Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development [ Gastroenterology, 2022, 162(4):1210-1225] PubMed: 34951993
Proton Pump Inhibitors Inhibit PHOSPHO1 Activity and Matrix Mineralisation In Vitro [ Calcif Tissue Int, 2021, 109(6):696-705] PubMed: 34213594
Proton pump inhibitors inhibit PHOSPHO1 activity and matrix mineralisation in vitro [ bioRxiv, 2021, 10.1101/2021.04.29.441931] PubMed: None
Histamine Receptor Antagonists, Loratadine and Azelastine, Sensitize P-gp-overexpressing Antimitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms. [ Anticancer Res, 2019, 39(7):3767-3775] PubMed: 31262903

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.